A preplanned early analysis of the Phase III TITAN trial shows that Erleada (apalutamide) has met the both of the trial’s primary endpoints in the treatment of men with metastatic castration-sensitive prostate cancer (CSPC).
There is a sad truth about the current state of affairs for the treatment of non-metastatic castration-resistant prostate cancer. Our treatments can best be described as being antiquated.
he FDA approved a new advanced hormone therapy drug (a next-generation androgen receptor inhibitor) for the treatment of men with non-metastatic castration-resistant prostate cancer (NM-CRPC). This drug with the trade name Erleada (aka apalutamide), is the first drug approved in this disease space.
Two different trials, SPARTAN and PROSPER, are reporting top-line results in the treatment of men with nmCRPC. The full results of these trials will be presented today at the Genitourinary Cancer Symposium in San Francisco where Cancer ABCs is in attendance.